Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area
- Authors
- Jin, Y.-J.; Lee, J.-W.; Lee, J.-I.; Park, S.H.; Park, C.K.; Kim, Y.S.; Jeong, S.-H.; Kim, Y.S.; Kim, J.H.; Hwang, S.G.; Rim, K.S.; Yim, H.J.; Cheong, J.Y.; Cho, S.W.; Lee, J.S.; Park, Y.M.; Jang, J.W.; Lee, C.K.; Sohn, J.H.; Yang, J.M.; Han, S.
- Issue Date
- 2012
- Keywords
- Chronic hepatitis C; Pegylated interferon alfa-2a; Pegylated interferon alfa-2b; Ribavirin; Sustained virological response
- Citation
- Journal of Antivirals and Antiretrovirals, v.4, no.4, pp.80 - 87
- Journal Title
- Journal of Antivirals and Antiretrovirals
- Volume
- 4
- Number
- 4
- Start Page
- 80
- End Page
- 87
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17492
- DOI
- 10.4172/jaa.1000050
- ISSN
- 1948-5964
- Abstract
- Background/Aim: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virological response (EVR), end-of-treatment response (ETR), and SVR rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values >0.05) and 2/3 (all P-values >0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values>0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values>0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis. © 2012 Jin YJ, et al.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17492)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.